DexCom Inc (DXCM) stock
DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3030% below fair value
$83.33+1.94 (+2.38%)
Close on Nov 13, 2026Market cap $31.08BP/E 32.8Yield –
DexCom ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
DexCom's ebitda for the twelve months ending Sep 30, 2026 was $1.50B, up 46.6% year over year. For fiscal 2025 it was $1.16B, up 42.3% from the year before. The highest annual figure on record is $1.16B in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.16B | +42.3% |
| FY2024 | Dec 31, 2024 | $817.70M | +4.3% |
| FY2023 | Dec 31, 2023 | $783.70M | +43.2% |
| FY2022 | Dec 31, 2022 | $547.10M | +48.7% |
| FY2021 | Dec 31, 2021 | $367.80M | +0.3% |
| FY2020 | Dec 31, 2020 | $366.60M | +91.9% |
| FY2019 | Dec 31, 2019 | $191.00M | – |
| FY2018 | Dec 31, 2018 | -$157.20M | – |
| FY2017 | Dec 31, 2017 | -$26.40M | – |
| FY2016 | Dec 31, 2016 | -$48.90M | – |
| FY2015 | Dec 31, 2015 | -$46.30M | – |
| FY2014 | Dec 31, 2014 | -$13.10M | – |
| FY2013 | Dec 31, 2013 | -$21.90M | – |
| FY2012 | Dec 31, 2012 | -$49.10M | – |
| FY2011 | Dec 31, 2011 | -$41.00M | – |
| FY2010 | Dec 31, 2010 | -$42.90M | – |
| FY2009 | Dec 31, 2009 | -$43.46M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $401.70M | +31.2% |
| Q2 FY2026 | Jun 30, 2026 | $386.50M | +40.2% |
| Q1 FY2026 | Mar 31, 2026 | $322.40M | +66.4% |
| Q4 FY2025 | Dec 31, 2025 | $388.20M | +57.4% |
| Q3 FY2025 | Sep 30, 2025 | $306.10M | +47.7% |
| Q2 FY2025 | Jun 30, 2025 | $275.60M | +31.2% |
| Q1 FY2025 | Mar 31, 2025 | $193.70M | +26.1% |
| Q4 FY2024 | Dec 31, 2024 | $246.70M | -8.4% |
| Q3 FY2024 | Sep 30, 2024 | $207.30M | -18.3% |
| Q2 FY2024 | Jun 30, 2024 | $210.10M | +22.3% |
| Q1 FY2024 | Mar 31, 2024 | $153.60M | +73.0% |
| Q4 FY2023 | Dec 31, 2023 | $269.40M | +66.6% |
| Q3 FY2023 | Sep 30, 2023 | $253.70M | +35.9% |
| Q2 FY2023 | Jun 30, 2023 | $171.80M | +42.5% |
| Q1 FY2023 | Mar 31, 2023 | $88.80M | +13.7% |
| Q4 FY2022 | Dec 31, 2022 | $161.70M | +394.5% |
| Q3 FY2022 | Sep 30, 2022 | $186.70M | +29.8% |
| Q2 FY2022 | Jun 30, 2022 | $120.60M | -3.1% |
| Q1 FY2022 | Mar 31, 2022 | $78.10M | +16.9% |
| Q4 FY2021 | Dec 31, 2021 | $32.70M | -73.7% |
| Q3 FY2021 | Sep 30, 2021 | $143.80M | +27.8% |
| Q2 FY2021 | Jun 30, 2021 | $124.50M | +49.8% |
| Q1 FY2021 | Mar 31, 2021 | $66.80M | +43.3% |
| Q4 FY2020 | Dec 31, 2020 | $124.40M | +7.4% |
| Q3 FY2020 | Sep 30, 2020 | $112.50M | +63.3% |
| Q2 FY2020 | Jun 30, 2020 | $83.10M | +669.4% |
| Q1 FY2020 | Mar 31, 2020 | $46.60M | – |
| Q4 FY2019 | Dec 31, 2019 | $115.80M | – |
| Q3 FY2019 | Sep 30, 2019 | $68.90M | +217.5% |
| Q2 FY2019 | Jun 30, 2019 | $10.80M | +500.0% |
| Q1 FY2019 | Mar 31, 2019 | -$4.50M | – |
| Q4 FY2018 | Dec 31, 2018 | -$156.00M | -1063.0% |
| Q3 FY2018 | Sep 30, 2018 | $21.70M | +471.1% |
| Q2 FY2018 | Jun 30, 2018 | $1.80M | – |
| Q1 FY2018 | Mar 31, 2018 | -$24.70M | – |
| Q4 FY2017 | Dec 31, 2017 | $16.20M | – |
| Q3 FY2017 | Sep 30, 2017 | $3.80M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.70M | – |
| Q1 FY2017 | Mar 31, 2017 | -$36.70M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.50M | – |
See a number that looks wrong?